Showing 5221-5230 of 10601 results for "".
- ctDNA Outperforms MCPyV Antibody Testing for Merkel Cell Carcinoma Surveillancehttps://practicaldermatology.com/news/ctdna-outperforms-mcpyv-antibody-testing-for-merkel-cell-carcinoma-surveillance/2487805/Circulating tumor DNA (ctDNA) may provide a more accurate method for detecting recurrence of Merkel cell carcinoma (MCC) than the currently available Merkel cell polyomavirus (MCPyV) oncoprotein antibody test, according to results from a multicenter US cohort study
- New Data Support 24-Week Abrocitinib Tapering in Controlled ADhttps://practicaldermatology.com/news/new-data-support-24-week-abrocitinib-tapering-in-controlled-ad/2487773/New data published in the Journal of the American Academy of Dermatology suggests tapering abrocitinib may be a feasible strategy for patients with moderate-to-severe atopic dermatitis (AD) who have achieved an adequate clin
- CuralysMD Launches Steroid-Free Eczema Lotion Focused on Skin Barrier Supporthttps://practicaldermatology.com/news/curalysmd-launches-steroid-free-eczema-lotion-focused-on-skin-barrier-support/2487770/CuralysMD announced the unveiling of a new over-the-counter eczema skin protectant lotion designed to support skin barrier repair in patients with mild to moderate eczema. The steroid-free formulation contains colloidal oatme
- Report: Dermatology M&A Momentum Sets Sights on Independent Practiceshttps://practicaldermatology.com/news/dermatology-ma-momentum-continues-as-buyers-chase-independent-practices/2487714/Private equity investment in dermatology continues at a rapid pace in 2026, with buyer demand remaining strong despite more than a decade of consolidation across the specialty, according to a new market update from Physician Growth Partners.
- Consensus Panel Offers First Standardized Imaging Framework for High-Risk CSCChttps://practicaldermatology.com/news/consensus-panel-offers-first-standardized-imaging-framework-for-high-risk-cscc/2487708/A multidisciplinary panel of experts has developed consensus recommendations to help standardize staging and surveillance imaging for patients with localized cutaneous squamous cell carcinoma (cSCC), publishing the recommendations online in
- FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With ADhttps://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-005-in-infants-with-atopic-dermatitis/2487703/The US Food and Drug Administration (FDA) anounced that it has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) seeking to expand the indication for ZORYVE (roflumilast) cream 0.05% to include infants aged 3 to 24 months with mild to mode
- Picankibart Shows Skin Clearance in Plaque Psoriasis: Analysishttps://practicaldermatology.com/news/picankibart-shows-skin-clearance-in-plaque-psoriasis/2487695/A phase III study published in the Journal of the American Academy of Dermatology found that picankibart, an investigational interleukin (IL)-23p19 inhibitor, produced high rates of skin clearance with durable efficacy throu
- Study: Dupilumab Shows Long-Term Disease Control in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/study-dupilumab-shows-long-term-disease-control-in-pediatric-atopic-dermatitis/2487681/Children and adolescents with moderate-to-severe atopic dermatitis (AD) maintained improvements in disease signs and symptoms during 1 year of dupilumab treatment, according to a post hoc analysis of the ongoing phase 3 LIBERTY AD PED-OLE open-label extension study
- Meta-analysis: Topical Ivermectin, Encapsulated BPO Show Strongest Efficacy in Rosaceahttps://practicaldermatology.com/news/topical-ivermectin-encapsulated-benzoyl-peroxide-show-strongest-efficacy-in-rosacea-network-meta-analysis/2487668/A systematic review and network meta-analysis of randomized clinical trials suggests that topical ivermectin and encapsulated benzoyl peroxide (E-BPO) provide greater efficacy than metronidazole for adults with moderate to severe rosacea.
- FDA Grants SKYRIZI Approval to Children With Plaque Psoriasis and PsAhttps://practicaldermatology.com/news/fda-expands-skyrizi-approval-to-include-children-with-plaque-psoriasis-and-psoriatic-arthritis/2487657/The FDA has expanded the indication for SKYRIZI® (risankizumab-rzaa) to include children aged 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, according to an announcement from AbbVie.